Cellulite is one of the most common and most stubborn conditions in aesthetic medicine. It affects an estimated 80–90% of post-pubertal women regardless of weight or fitness, and it is the reason a multi-billion treatment industry exists. It is also a field where the marketing runs far ahead of the evidence: creams, brushes, massages, and at-home devices promise smoothing while doing little to the structural cause.
This article maps what the clinical-trial record and the FDA clearances actually support. It is built from 62 cellulite trials registered on ClinicalTrials.gov, the FDA labels and clearance summaries for the devices and drugs that reached the U.S. market, and the published pivotal-trial data behind them. The goal is to separate the treatments that act on the cause of cellulite from the ones that act on its appearance — and to be honest about how long each lasts.
What cellulite actually is (and why it resists effort)
Cellulite is not "toxins," not a sign of poor health, and not something diet or exercise eliminates. It is a structural condition. Beneath the skin, fibrous bands called septae connect the skin to the underlying muscle fascia. In cellulite, these septae shorten and tether the skin downward while the fat lobules between them push upward — producing the characteristic dimples, most often on the buttocks and thighs. Women are far more affected than men because of differences in septal architecture, fat distribution, and hormones; estrogen plays a role, which is why cellulite emerges after puberty and is near-universal in women.
This anatomy explains three things that confuse patients. First, thin people get cellulite — it is about septal tethering, not fat volume. Second, weight loss can make cellulite more visible, not less, as the deflating fat lobules make the tethers more prominent. Third, anything that treats only the skin surface — creams, caffeine, massage, dry brushing — can produce a temporary, minor smoothing but cannot release the septae. The treatments with real evidence are the ones that act on the bands beneath the skin.
What 62 clinical trials actually studied
A review of 62 cellulite trials registered on ClinicalTrials.gov shows where the research effort has concentrated.
| Trial characteristic | Count |
|---|---|
| Total cellulite trials | 62 |
| By intervention type | |
| Device-based | 36 |
| Drug (injectable) | 12 |
| Biological | 9 |
| Other | 6 |
| Procedure | 2 |
| By phase | |
| Device / no phase (NA) | 33 |
| Phase 2 | 10 |
| Phase 4 | 8 |
| Phase 3 | 4 |
| Phase 1 | 3 |
| By status | |
| Completed | 51 |
| Unknown status | 5 |
| Terminated | 4 |
| Suspended / not recruiting | 2 |
Two patterns stand out. First, device-based treatments dominate the research — 36 of 62 trials — reflecting an industry that has iterated through subcision blades, lasers, radiofrequency, cryolipolysis, and most recently acoustic pulses. Second, the injectable track is real but narrow: a single collagenase-based injectable — collagenase clostridium histolyticum-aaes, branded Qwo and developed under the code EN3835 — accounts for the bulk of the drug and biological trials. Only a handful of cellulite trials ever reached Phase 3, which is typical of a field where most cleared products enter through the device pathway rather than through drug approval.
The injectable that came and went: Qwo
Qwo (collagenase clostridium histolyticum-aaes) was the first — and so far only — injectable ever approved by the FDA for cellulite. Approved in 2020 for the treatment of moderate to severe cellulite in the buttocks of adult women, it worked by enzymatic subcision: a purified bacterial enzyme injected directly into the dimple to dissolve the collagen-rich septae tethering the skin.
The mechanism was sound. Clinical trials showed real improvement in dimpling, and Qwo was genuinely novel — a needle-only treatment that released the bands without a blade or laser. The problem was not efficacy but tolerability. In the pivotal trials, 84% of subjects experienced injection-site bruising, a rate the label flags explicitly. In real-world use, that bruising proved more extensive and more variable than many patients and providers expected, and there was a risk of prolonged skin discoloration — specifically hemosiderin staining, an iron pigment left behind by ruptured red blood cells in the bruised tissue that can take months to fade.
On December 6, 2022, Endo International announced it would cease production and sale of Qwo, citing the extent and variability of bruising after initial treatment and the potential for prolonged skin discoloration. The product remained FDA-approved — it was a commercial and tolerability decision, not a safety withdrawal — and practices were permitted to use remaining unexpired stock. But as a widely available injectable, Qwo is gone. Its commercial failure is instructive: the first product to make enzymatic subcision work did not survive patient experience with the bruising that mechanism predictably causes.
EN3835 was Qwo's own development code — the Qwo pivotal trials appear in ClinicalTrials.gov under that name — so the "EN3835" trials in the dataset are the Qwo studies themselves, not a separate successor. No follow-on collagenase injectable has reached the U.S. market since Qwo's withdrawal. For now, the FDA-cleared cellulite options are all device- or procedure-based.
What the FDA has cleared, and the evidence behind each
With the injectable path closed for the moment, the cellulite treatments with FDA clearance are devices and procedures. They differ in invasiveness, durability, and how much evidence supports them.
Subcision — the longest-lasting option
The best-supported approach mechanically releases the septae. Cellfina (Merz), FDA-cleared for the improvement of cellulite on the buttocks and thighs, uses a vacuum-assisted microblade to cut the fibrous bands a few millimeters beneath the skin under local anesthesia. Its pivotal multicenter study (Kaminer et al., 2017, Dermatologic Surgery) reported patient satisfaction of 85% at three months and 96% at two years, with benefits persisting beyond three years on follow-up — the longest durability of any FDA-cleared cellulite treatment. Cellfina works best on discrete "dimple" cellulite (the structural bands), not on diffuse "wave" or textural cellulite.
Avéli is a newer FDA-cleared handheld subcision device that releases individual septae under real-time guidance, letting the provider confirm each band is cut before moving on. In the manufacturer's clinical study (published in the Aesthetic Surgery Journal), treated dimples showed a clinically significant reduction in cellulite that was maintained at one year, and some surgeons now position it as the leading option for discrete dimples precisely because each tether can be treated and verified. Like Cellfina, Avéli addresses the structural bands, not diffuse skin texture. Typical cost runs $3,000–$6,500 for Cellfina and $3,000–$7,000 for Avéli, varying by area and geography. Manual subcision with a plain needle uses the same principle but offers less control over depth and area.
Acoustic pulses — the single-session non-invasive option
RESONIC (Soliton, now part of a larger aesthetic portfolio), FDA-cleared for cellulite, delivers Rapid Acoustic Pulses — high-peak-power sound waves that disrupt the septae in a single treatment session, an approach sometimes called "acoustic subcision." Unlike Cellfina, RESONIC is non-invasive: no needles, no incisions, and minimal to no downtime. Pivotal data reported improvement in the majority of treated dimples after one session. It is the newest entrant in the cleared set, so long-term durability data is still accumulating.
Traditional acoustic wave therapy (radial shockwave devices such as Zimmer Z-Wave, Storz Cellactor) uses lower-energy sound waves over a course of sessions. Meta-analyses have shown modest improvement, but the effect is comparatively small and requires maintenance.
Laser subcision
Cellulaze (Cynosure), FDA-cleared, inserts a tiny laser fiber under the skin to heat and release the septae and thicken the dermis. Published results show improvement lasting roughly one to two years. It is minimally invasive (a small incision and local anesthesia) and sits between Cellfina and fully non-invasive options on both durability and recovery.
Radiofrequency and energy platforms
RF-based devices (Venus Legacy, VelaShape, Evolve Trim, and others) heat the dermis to thicken skin and temporarily improve the appearance of cellulite. They are non-invasive and require multiple sessions, with results typically lasting a few months. They are reasonable for textural improvement and maintenance, but they do not release the septae, so the effect is shorter and more modest than subcision.
What does not work (well enough to matter)
- Topical creams (caffeine, retinol) produce at most a slight, temporary firming of the skin surface. They cannot reach or release the septae.
- Dry brushing and massage improve lymphatic drainage and skin texture briefly but do not change the structural cause.
- Weight loss alone does not treat cellulite and can accentuate dimpling.
- Liposuction removes fat volume but does not release septae and can worsen the appearance of cellulite in some cases.
Realistic expectations
No cellulite treatment is permanent. The cleared options reduce, rather than erase, dimpling, and the bands can re-form or new ones become apparent over time. The practical ladder, drawn from the clearance record, pivotal data, and market pricing, looks roughly like this:
| Treatment | Mechanism | Invasiveness | Approximate durability | Typical cost (USD) |
|---|---|---|---|---|
| Cellfina / Avéli subcision | Cuts septae | Minimally invasive | 3+ years | $3,000–$7,000 |
| RESONIC (acoustic) | Disrupts septae | Non-invasive | Newer; single session | $3,000–$5,000+ |
| Cellulaze (laser) | Laser release + dermal thickening | Minimally invasive | 1–2 years | $3,500–$6,000 |
| Acoustic wave therapy (radial) | Mechanical stimulation | Non-invasive | Months (maintenance) | $200–$500 / session |
| Radiofrequency platforms | Dermal heating/thickening | Non-invasive | Months | Varies; package pricing |
| Topicals, massage, brushing | Surface only | None | Negligible / temporary | Low |
Costs vary widely by geography, practice, and number of areas treated, and cellulite treatment is cosmetic, so it is not covered by insurance.
Matching the treatment to the cellulite type matters more than matching it to the brand. Dimple-type cellulite (clear structural bands) responds to subcision and acoustic release. Diffuse, textural, or "wave" cellulite responds better to dermal-thickening modalities (RF, laser) — and responds more modestly. A provider who evaluates which type you have before recommending a device is doing the work correctly; a clinic that leads with one device for everyone is not.
What to ask before cellulite treatment
- Which type of cellulite do I have — discrete dimples (structural bands) or diffuse texture — and is this treatment aimed at the bands or at the skin?
- What is FDA-cleared vs. off-label here? Cellfina, RESONIC, Cellulaze, and the RF platforms have specific clearances; some devices are used off-label for cellulite.
- What is the expected durability, and what does maintenance cost? Get a number in years, not vague reassurance.
- For subcision: how many dimples are treated per session, and what is the bruising and recovery like? Cellfina recovery is typically 24–48 hours of soreness and bruising.
- Is the clinic recommending the right tool for my cellulite, or the only tool it owns? The answer should involve an assessment of dimple type first.
- If offered an injectable for cellulite, what is it? Qwo is no longer produced; any cellulite injectable in 2026 should be identified clearly and its approval status confirmed.
Patients should be cautious of any cellulite injectable presented as "like Qwo" or sold without clear FDA approval status, and of any device promising permanent or dramatic correction. Cellulite is a structural condition that can be meaningfully improved by the right treatment — and meaningfully overpromised by the wrong one. Adverse events can be reported to the FDA through the MedWatch system.
Sources
- Endo International — Endo to Cease Production and Sale of Qwo (collagenase clostridium histolyticum-aaes), Dec 6, 2022: https://investor.endo.com/2022-12-06-Endo-to-Cease-Production-and-Sale-of-Qwo-R-collagenase-clostridium-histolyticum-aaes
- FDA — QWO (collagenase clostridium histolyticum-aaes) Prescribing Information, BLA 761146 (2020 label): https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761146s000lbl.pdf
- American Board of Cosmetic Surgery — What happened to QWO, the cellulite injectable? https://www.americanboardcosmeticsurgery.org/blog/what-happened-to-qwo-the-cellulite-injectable
- Kaminer MS, Coleman WP, Weiss RA, Robinson DM, Grossman J. A multicenter pivotal study to evaluate tissue stabilized-guided subcision using the Cellfina device for the treatment of cellulite with 3-year follow-up. Dermatol Surg. 2017;43(10):1240–1248. (Referenced via review at PubMed.)
- Avéli (Revelle Aesthetics) — CONFFIRM multicenter pivotal study of targeted verifiable subcision for cellulite, final results at 12 months (NCT04743635). Aesthetic Surgery Journal; PubMed: https://pubmed.ncbi.nlm.nih.gov/36351188
- American Board of Cosmetic Surgery — Cellulite Reduction Treatments: https://www.americanboardcosmeticsurgery.org/cosmetic-procedures/non-surgical/cellulite-treatments
- Hexsel D, Mazzuco R. Cellulite: An Evidence-Based Review. Am J Clin Dermatol. 2015;16(4):243–256.
- Sadick N, et al. Treatment for cellulite (evidence-based review). PMC6374708: https://pmc.ncbi.nlm.nih.gov/articles/PMC6374708
- The PMFA Journal — Cellulite therapy in 2022 (RESONIC Rapid Acoustic Pulse technology): https://www.thepmfajournal.com/features/features/post/cellulite-therapy-in-2022-new-treatment-options-making-grades-for-the-new-year
- American Society of Plastic Surgeons — Cellulite treatment information: https://www.plasticsurgery.org/cosmetic-procedures/cellulite-treatment
- FDA — Aesthetic and Cosmetic Devices: https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices
Analysis sample: ClinicalTrials.gov extract dated 2026-06-10, 62 registered clinical trials listing cellulite as a condition or intervention term. Trial counts are of registered studies and include completed, terminated, and unknown-status trials; they are not a measure of efficacy. Durability figures are drawn from FDA clearance language and pivotal-trial publications cited above. Analysis by AestheticMedGuide.
